Evidence map›Paper›PMID 40151077›Full record

ArticleCurrent neuropharmacology2025

Synthetic Derivates of Progesterone Ameliorate Scopolamine-Induced Cognitive Deficits in Animal Models: Antioxidant, Enzyme Inhibitory, Molecular Docking and Behavioral Correlates.

Asif Nawaz, Abdul Sadiq, Nasreena Bashir, Umer Rashid, Farhat Ullah, Shahbaz Khan, Farman Ullah, Mohammad Inam Khan, Muhammad Ayaz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Asif NawazDepartment of Pharmacy, Faculty of Biological Sciences, University of Malakand, Chakdara, 18800 Dir (L), Khyber Pakhtunkhwa, Pakistan.
Abdul SadiqDepartment of Pharmacy, Faculty of Biological Sciences, University of Malakand, Chakdara, 18800 Dir (L), Khyber Pakhtunkhwa, Pakistan.
Nasreena BashirDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, 61421, Saudi Arabia.
Umer RashidDepartment of Chemistry, COMSATS University Islamabad, 22060 Abbottabad, Pakistan.
Farhat UllahDepartment of Pharmacy, Faculty of Biological Sciences, University of Malakand, Chakdara, 18800 Dir (L), Khyber Pakhtunkhwa, Pakistan.
Shahbaz KhanKhyber Medical College, Khyber Medical University, Peshawar, Pakistan.
Farman UllahDepartment of Pharmacy, Kohat University of Science and Technology (KUST), Khyber Pakhtunkhwa (KP), Pakistan.
Mohammad Inam KhanPublic Health Department, College of Health Sciences, Saudi Electronic University, Abha Male 61421, Saudi Arabia.
Muhammad AyazDepartment of Pharmacy, Faculty of Biological Sciences, University of Malakand, Chakdara, 18800 Dir (L), Khyber Pakhtunkhwa, Pakistan.

Funding

Deanship of Research and Graduate Studies at King Khalid University RGP1/133/45
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a neurological disorder characterized by cognitive decline and behavioral distrubance which are expected to significantly affect the patient's quality of life. Previous studies revealed the neuroprotective effects of progesterone. Furthermore, the aim of this study was to assess the neuroprotective potentials of new derivatives of progesterone (AN-1 to AN-5).

methodsFollowing compound synthesis and structure elucidation, in vitro antioxidant (DPPH), acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities, as well as molecular docking studies, were performed, according to the standard procedures and the most potent compound was then subjected to more detailed behavioral studies, including the Y-Maze, Elevated Plus Maze (EPM), and open field tests in scopolamine-induced amnesic animals.

resultsIn the DPPH assay, the AN-1 compound at 1000 μg/ml concentration exhibited 83.37 ± 2.03% inhibition of DPPH free radicals with an IC

conclusionBased on our findings, it is concluded that the derivatives of progesterone exhibit neuroprotective potential, and further research is needed to extend their neuroprotective role in the treatment of AD.

Indexed as

AntioxidantsCholinesterase InhibitorsCognitive DysfunctionNeuroprotective AgentsProgesteroneAcetylcholinesteraseAnimalsButyrylcholinesteraseDisease Models, AnimalMaleMaze LearningMolecular Docking SimulationRatsRats, WistarScopolamineAcetylcholinesteraseAntioxidantsButyrylcholinesteraseCholinesterase InhibitorsNeuroprotective AgentsProgesteroneScopolamineAlzheimer’s diseaseantioxidants.cholinesterase’sNeuroprotectionprogesteronesteroids

Identifiers

PMID40151077
PMCPMC12645137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.